Biomarkers in Urologic Cancer, An Issue of Urologic Clinics of North America, 1st Edition
Author :
Kevin R. Loughlin
The past decade has been marked by the acceleration of our understanding of the molecular biology of cancer. Simultaneously, there have been increasing exigencies to diagnose, treat and follow cancer patients more economically. Biomarkers represent t
...view more
The past decade has been marked by the acceleration of our understanding of the molecular biology of cancer. Simultaneously, there have been increasing exigencies to diagnose, treat and follow cancer patients more economically. Biomarkers represent the marriage of science and economics. Biomarkers offer the potential to increase the precision of diagnosis, prognosis, and surveillance of urological malignancies. This issue presents the cutting-edge advances of biomarker technology to urologic oncology.
The past decade has been marked by the acceleration of our understanding of the molecular biology of cancer. Simultaneously, there have been increasing exigencies to diagnose, treat and follow cancer patients more economically. Biomarkers represent the marriage of science and economics. Biomarkers offer the potential to increase the precision of diagnosis, prognosis, and surveillance of urological malignancies. This issue presents the cutting-edge advances of biomarker technology to urologic oncology.
Author Information
By Kevin R. Loughlin, MD, MBA, Emeritus Professor of Surgery (Urology), Harvard Medical School, Visiting Scientist, Vascular Biology Research Program at Boston Children’s Hospita
https://www.us.elsevierhealth.com/biomarkers-in-urologic-cancer-an-issue-of-urologic-clinics-of-north-america-9780323417181.html2114Biomarkers in Urologic Cancer, An Issue of Urologic Clinics of North Americahttps://www.us.elsevierhealth.com/media/catalog/product/9/7/9780323417181.jpg79.1998.99USDInStock/Medicine/Urology/Clinics/Clinics12843887255255041The past decade has been marked by the acceleration of our understanding of the molecular biology of cancer. Simultaneously, there have been increasing exigencies to diagnose, treat and follow cancer patients more economically. Biomarkers represent the marriage of science and economics. Biomarkers offer the potential to increase the precision of diagnosis, prognosis, and surveillance of urological malignancies. This issue presents the cutting-edge advances of biomarker technology to urologic oncology. The past decade has been marked by the acceleration of our understanding of the molecular biology of cancer. Simultaneously, there have been increasing exigencies to diagnose, treat and follow cancer patients more economically. Biomarkers represent the marriage of science and economics. Biomarkers offer the potential to increase the precision of diagnosis, prognosis, and surveillance of urological malignancies. This issue presents the cutting-edge advances of biomarker technology to urologic oncology.00add-to-cart97803234171812015ProfessionalBy Kevin R. Loughlin, MD, MBA20161BookOtherElsevier0Dec 6, 2015IN STOCK - This may take up to 5 business days to shipBy <STRONG>Kevin R. Loughlin</STRONG>, MD, MBA, Emeritus Professor of Surgery (Urology), Harvard Medical School, Visiting Scientist, Vascular Biology Research Program at Boston Children’s HospitaClinicsClinicsThe Clinics: Internal MedicineNoNoNoNoPlease SelectPlease SelectPlease Select
